A Pre-ESMO POV: Efficient Clinical Trial and Approval Strategies in Oncology

In this pre-ESMO POV, Precision’s Chief Medical Officer, Gerry Messerschmidt, M.D., FACP, discusses the expected buzz at ESMO and highlights important factors to consider going into 2019, as advanced science and the regulatory landscape have created more opportunities for novel development and accelerated approval.

Get the Efficient Clinical Trial and Approval Strategies in Oncology

Precision Medicine Group is an integrated team of experts in fields from advanced lab sciences to translational informatics, adaptive clinical trial execution to regulatory affairs, payer insights to marketing communications. Together, we help our pharmaceutical and life-sciences clients conquer product development and commercialization challenges in a rapidly evolving environment.